Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Pancreatic Neoplasms: HELP
Articles by Anne Stehr
Based on 2 articles published since 2010
(Why 2 articles?)

Between 2010 and 2020, Anne Stehr wrote the following 2 articles about Pancreatic Neoplasms.
+ Citations + Abstracts
1 Article ABO blood group IgM isoagglutinins interact with tumor-associated O-glycan structures in pancreatic cancer. 2014

Hofmann, Bianca T / Stehr, Anne / Dohrmann, Thorsten / Güngör, Cenap / Herich, Lena / Hiller, Jens / Harder, Sönke / Ewald, Florian / Gebauer, Florian / Tachezy, Michael / Precht, Clarissa / Izbicki, Jakob R / Bockhorn, Maximilian / Wagener, Christoph / Wolters-Eisfeld, Gerrit. ·Department of General, Visceral and Thoracic Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. · Department of Clinical Chemistry, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. · Department of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Insitute of Medical Statistics, Informatics and Epidemiology (IMSIE) University Hospital of Cologne, Cologne, Germany. · Department of Transfusion Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. · Department of Hepatobiliary and Transplant Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. · Department of Oral and Maxillofacial Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. · Department of General, Visceral and Thoracic Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. ge.wolters@uke.de. ·Clin Cancer Res · Pubmed #25320359.

ABSTRACT: PURPOSE: The ABO gene locus is associated with the risk of developing pancreatic ductal adenocarcinoma (PDAC) resulting in an increased incidence in individuals with non-O blood groups. Up to 90% of PDAC specimens display alterations in mucin type O-GalNAc glycosylation. Because aberrant O-GalNAc glycans (Tn and T antigen) are structurally related to blood group A and B glycans, we investigated the role of IgM isoagglutinins in PDAC. EXPERIMENTAL DESIGN: Binding studies of IgM isoagglutinins toward blood group A, B, Tn antigen, and T antigen glycoconjugates from patients with PDAC and healthy individuals were conducted. Isoagglutinin titers and total IgM were compared between patients with PDAC and control group. An anti-A antibody was used for immunoprecipitation of aberrant O-glycosylated tumor proteins and subsequent mass spectromic analysis. RESULTS: We found that IgM isoagglutinins bind blood group antigens, Tn and T glycoconjugates as well as tumor-derived glycoproteins. Blood group A isoagglutinins exhibited a strong binding toward blood group B antigen and T antigen, whereas blood group B showed binding to blood group A antigen and Tn antigen. Furthermore, we confirmed a decreased frequency in individuals with blood group O and observed a significant decrease of IgM isoagglutinin titers in PDAC sera compared with control sera, whereas total IgM levels were unaltered. We identified new PDAC-derived O-GalNAc glycoproteins by mass spectrometry using a blood group A-specific antibody. CONCLUSION: Our data elucidated a novel interaction of blood group IgM isoagglutinins and PDAC O-GalNAc glycoproteins that may contribute to the pathogenesis and progression of pancreatic cancer.

2 Article Ultrasonic dissection versus conventional dissection techniques in pancreatic surgery: a randomized multicentre study. 2012

Uzunoglu, Faik G / Stehr, Anne / Fink, Judith A / Vettorazzi, Eik / Koenig, Alexandra / Gawad, Karim A / Vashist, Yogesh K / Kutup, Asad / Mann, Oliver / Gavazzi, Francesca / Zerbi, Alessandro / Bassi, Claudio / Dervenis, Christos / Montorsi, Marco / Bockhorn, Maximilian / Izbicki, Jakob R. ·Department of General, Visceral and Thoracic Surgery, University Medical Centre Hamburg-Eppendorf, Martinistraße 52, Hamburg, Germany. ·Ann Surg · Pubmed #23095609.

ABSTRACT: OBJECTIVE: : This prospective randomized multicenter trial was performed to assess the potential benefits of ultrasonic energy dissection compared with conventional dissection techniques in pancreatic surgery. BACKGROUND: : Surgical procedures for tumors of the pancreatic head involve time-consuming manual dissection. The primary hypothesis was that use of ultrasonic tissue and vessel dissection would lead to substantial saving in operative time during pancreatic resection. METHODS: : Patients eligible for pancreaticoduodenectomy (PD) or pylorus-preserving PD (PPPD) were randomized to group A (dissection with ultrasonic device) or group B (conventional dissection) from March 2009 to May 2011. The primary endpoint was overall duration of operation time. Secondary endpoints were time to end of resection phase, intraoperative blood loss, number of transfused units of blood, and postoperative morbidity. RESULTS: : Analysis of primary and secondary endpoints included 101 patients, who received either PD or PPPD. Demographical characteristics and clinical parameters were similar in both groups. The use of an ultrasonic dissection device did not significantly reduce overall operation time (median 316 minutes in group A and 319 minutes in group B, P = 0.95) and did not significantly increase the costs of surgery. Analysis of secondary endpoints revealed no difference in postoperative course. CONCLUSIONS: : Tissue dissection and vessel closure using an ultrasonic device is equivalent to dissection with conventional techniques in pancreatic surgery.